Functionalized organic oligomers using homogeneous modification method for molecular binding
View Patent ↗A method of homogeneously forming functionalized biocompatible oligomers includes the steps of dissolving a biocompatible oligomer in a solvent to form a solution, and admixing at least one π complex forming group to the solution, wherein the π complex forming group grafts to at least one location on the backbone of the oligomer to form a grafted oligomer. The oligomer is preferably oligochitosan and the solvent is preferably dimethylsulfoxide (DMSO). The degree of graft substitution can be at least 50%. The functionalized biocompatible oligomer can be used for drug detoxification through binding to a variety of target drugs.
1. A method of homogeneously forming biocompatible oligomer derivatives, comprising the steps of:
dissolving a biocompatible oligomer selected from the group consisting of oligochitin, oligochitosan, and derivatives thereof in a solvent to form a solution, and
admixing at least one π complex forming group into said solution,
wherein a grafted oligomer is formed, said grafted oligomer comprising at least one of said π complex forming groups grafted to a backbone of said oligomer, and
wherein said grafted oligomer is soluble in neutral water.
2. The method of claim 1 , wherein said solvent comprises dimethylsulfoxide (DMSO).
3. The method of claim 1 , wherein said solvent comprises at least one selected from the group consisting of gamma butyrolactone (GBL), propylene carbonate, N-methylpyrrolidinone (NMP), tetrahydrothiophen-1, 1-dioxide (TMS), polycarbonate (PC), methyl isobutyl ketone and dimethyl formamide (DMF).
4. The method of claim 1 , wherein said π complex forming group is at least one selected from the group consisting of benzenesulfonyl, dinitrobenzenesulfonyl, benzoyl, dinitrobenzoyl and naphthoyl.
5. The method of claim 1 , wherein said oligomer is selected from the group consisting of oligochitin and oligochitosan.
6. The method of claim 1 , wherein said biocompatible oligomer comprises oligochitosan, said oligochitosan having an average molecular weight of less than 3,000 Da.
7. The method of claim 1 , wherein a degree of substitution of said grafts is at least 20%.
8. The method of claim 1 , wherein a degree of substitution of said grafts is at least 40%.
9. The method of claim 1 , wherein said method provides a yield of said grafted oligomer of at least 40%.
10. A π-complex forming group functionalized biocompatible oligomer
which has been produced by the method of claim 1 .
11. The oligomer of claim 10 , wherein said oligomer is selected from the group consisting of oligochitin and oligochitosan.
12. The oligomer of claim 10 , wherein said oligomer comprises an oligochitosan, wherein a degree of substitution of said π complex forming group is at least 20%.
13. The oligomer of claim 10 , wherein said π complex forming group is at least one selected from the group consisting of benzenesulfonyl, dinitrobenzenesulfonyl, benzoyl, dinitrobenzoyl and naphthoyl.
14. The oligomer of claim 10 , wherein said biocompatible oligomer comprises oligochitosan, said oligochitosan having an average molecular weight of less than 3,000 Da.
15. The method of claim 1 , wherein said π complex forming group is π-accepting.
16. The oligomer of claim 10 , wherein said π complex forming group is π-accepting.